HB 22-1116

House Bill 22-1116, also known as the Plant-based Medicines bill, establishes a panel to study how certain plant-based medicines can help with mental health. The panel will focus on hallucinogenic compounds like psilocybin and others for one year and then report their findings and suggestions to lawmakers and the governor. This bill has been signed into law, meaning it is now active and the panel will start its work as planned.

Official Summary

The bill creates the plant-based medicine policy review panel (policy review panel). The purpose of the policy review panel is to study the use of plant-based medicines to support mental health. The policy review panel operates for one year. The policy review panel shall submit a report on its findings and policy recommendations to the house of representatives public and behavioral health and human services committee and the senate health and human services committee, or any successor committees; the governor; and the department of human services. The bill defines "plant-based medicine" as a naturally occurring hallucinogenic plant-based compound. Forms of plant-based medicine only include psilocybin, psilocyn, dimethyltryptamine, and ibogaine. (Note: This summary applies to this bill as introduced.)